BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 1517684)

  • 1. Treatment of Wilson's disease with zinc: X. Intestinal metallothionein induction.
    Yuzbasiyan-Gurkan V; Grider A; Nostrant T; Cousins RJ; Brewer GJ
    J Lab Clin Med; 1992 Sep; 120(3):380-6. PubMed ID: 1517684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zinc therapy increases duodenal concentrations of metallothionein and iron in Wilson's disease patients.
    Sturniolo GC; Mestriner C; Irato P; Albergoni V; Longo G; D'Incà R
    Am J Gastroenterol; 1999 Feb; 94(2):334-8. PubMed ID: 10022625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paradigm shift in treatment of Wilson's disease: zinc therapy now treatment of choice.
    Hoogenraad TU
    Brain Dev; 2006 Apr; 28(3):141-6. PubMed ID: 16466879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Wilson's disease with zinc. XIII: Therapy with zinc in presymptomatic patients from the time of diagnosis.
    Brewer GJ; Dick RD; Yuzbasiyan-Gurkan V; Johnson V; Wang Y
    J Lab Clin Med; 1994 Jun; 123(6):849-58. PubMed ID: 8201263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Wilson's disease with zinc. VI. Initial treatment studies.
    Brewer GJ; Yuzbasiyan-Gurkan V; Lee DY; Appelman H
    J Lab Clin Med; 1989 Dec; 114(6):633-8. PubMed ID: 2592853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Wilson's disease with zinc: III. Prevention of reaccumulation of hepatic copper.
    Brewer GJ; Hill GM; Dick RD; Nostrant TT; Sams JS; Wells JJ; Prasad AS
    J Lab Clin Med; 1987 May; 109(5):526-31. PubMed ID: 3572199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zinc therapy induction of intestinal metallothionein in Wilson's disease.
    Brewer GJ
    Am J Gastroenterol; 1999 Feb; 94(2):301-2. PubMed ID: 10022620
    [No Abstract]   [Full Text] [Related]  

  • 8. The interactions of penicillamine with copper in vivo and the effect on hepatic metallothionein levels and copper/zinc distribution: the implications for Wilson's disease and arthritis therapy.
    McQuaid A; Lamand M; Mason J
    J Lab Clin Med; 1992 Jun; 119(6):744-50. PubMed ID: 1593220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interactions of zinc and molybdenum with copper in therapy of Wilson's disease.
    Brewer GJ
    Nutrition; 1995; 11(1 Suppl):114-6. PubMed ID: 7749256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Copper in the feces--a marker for the effectiveness of zinc in the treatment of Wilson's disease].
    Dastych M
    Z Gastroenterol; 1990 Aug; 28(8):389-91. PubMed ID: 2275259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Control of the therapeutic prevention of copper uptake in the liver in Wilson's disease following oral administration of 64Cu].
    Günther K; Siegemund R; Lössner J; Kühn HJ
    Radiobiol Radiother (Berl); 1988; 29(2):226-9. PubMed ID: 3399664
    [No Abstract]   [Full Text] [Related]  

  • 12. [The role of zinc in the initial treatment of Wilson's disease in children].
    Cacić M; Percl M; Jadresin O; Kolacek S
    Lijec Vjesn; 2000 Mar; 122(3-4):77-81. PubMed ID: 10932534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of Wilson's disease with zinc. XVII: treatment during pregnancy.
    Brewer GJ; Johnson VD; Dick RD; Hedera P; Fink JK; Kluin KJ
    Hepatology; 2000 Feb; 31(2):364-70. PubMed ID: 10655259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Wilson's disease: a new gene and an animal model for an old disease.
    Cuthbert JA
    J Investig Med; 1995 Aug; 43(4):323-36. PubMed ID: 7552582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pathogenesis and treatment of Wilson's disease].
    Nagy J; Vincze Z; Folhoffer A; Horváth A; Csák T; Zelkó R
    Acta Pharm Hung; 2003; 73(4):237-41. PubMed ID: 15279036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zinc treatment prevents lipid peroxidation and increases glutathione availability in Wilson's disease.
    Farinati F; Cardin R; D'inca R; Naccarato R; Sturniolo GC
    J Lab Clin Med; 2003 Jun; 141(6):372-7. PubMed ID: 12819634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Oral zinc in Wilson disease--an alternative to D-penicillamine].
    Ramadori G; Keidl E; Hütteroth T; Dormeyer HH; Manns M; Meyer zum Büschenfelde KH
    Z Gastroenterol; 1985 Jan; 23(1):25-9. PubMed ID: 4060799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic copper and metallothionein distribution in Wilson's disease (hepatolenticular degeneration).
    Nartey NO; Frei JV; Cherian MG
    Lab Invest; 1987 Oct; 57(4):397-401. PubMed ID: 3312808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zinc therapy in Wilson's disease: observations in five patients.
    Rossaro L; Sturniolo GC; Giacon G; Montino MC; Lecis PE; Schade RR; Corazza GR; Trevisan C; Naccarato R
    Am J Gastroenterol; 1990 Jun; 85(6):665-8. PubMed ID: 2353684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Wilson's disease with zinc. VII. Protection of the liver from copper toxicity by zinc-induced metallothionein in a rat model.
    Lee DY; Brewer GJ; Wang YX
    J Lab Clin Med; 1989 Dec; 114(6):639-45. PubMed ID: 2592854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.